Metformin is not associated with improved biochemical free survival or cause-specific survival in men with prostate cancer treated with permanent interstitial brachytherapy

Journal of Contemporary Brachytherapy

Volumn 6, Issue 3, 2014, Pages 254-261

  Taira, Al V ^a   Merrick, Gregory S ^b,c   Galbreath, Robert W ^b,d   Morris, Mallory ^b   Butler, Wayne M ^b   Adamovich, Edward ^c  

^a Mills Peninsula Health Services   (United States)

^b WHEELING JESUIT UNIVERSITY   (United States)

^c WHEELING HOSPITAL   (United States)

^d Ohio University Eastern   (United States)

Author keywords

Brachytherapy; Diabetes mellitus; LDR; Metformin; Prostate cancer; Seeds

Indexed keywords

METFORMIN;

AGED; ARTICLE; BIOCHEMICAL FREE SURVIVAL; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CAUSE SPECIFIC SURVIVAL; COHORT ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROSTATE CANCER; SURVIVAL;

EID: 84907690801     PISSN: 1689832X     EISSN: 20812841     Source Type: Journal    
DOI: 10.5114/jcb.2014.45757     Document Type: Article

References (22)

1. Decensi A, Puntoni M, Goodwin P et al. Metformin and cancer risk in diabetic patients: A systematic review and metaanalysis. Cancer Prev Res (Phila) 2010; 3: 1451-1461.
2. Lee MS, Hsu CC, Wahlqvist ML et al. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: A representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011; 11: 20.
3. Libby G, Donnelly LA, Donnan PT et al. New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 2009; 32: 1620-1625.
4. Ruiter R, Visser LE, van Herk-Sukel MP et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: Results from a large population-based follow-up study. Diabetes Care 2012; 35: 119-124.
5. Noto H, Goto A, Tsujimoto T et al. Cancer risk in diabetic patients treated with metformin: A systematic review and metaanalysis. PloS One 2012; 7: E33411.
6. Margel D, Urbach DR, Lipscombe LL et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 2013; 31: 3069-3075.
7. Yin M, Zhou J, Gorak EJ et al. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: A systematic review and meta-analysis. Oncologist 2013; 18: 1248-1255.
8. Ben Sahra I, Laurent K, Loubat A et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576-3586.
9. Zakikhani M, Dowling R, Fantus IG et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269-10273.
10. He XX, Tu SM, Lee MH et al. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 2011; 22: 2640-2645.
11. Spratt DE, Zhang C, Zumsteg ZS et al. Metformin and prostate cancer: Reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013; 63: 709-716.
12. Allott EH, Abern MR, Gerber L et al. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: Results from the SEARCH database. Prostate Cancer Prostatic Dis 2013; 16: 391-397.
13. Kaushik D, Karnes RJ, Eisenberg MS et al. Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol 2014; 32: 43.e41-47.
14. Patel T, Hruby G, Badani K et al. Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 2010; 76: 1240-1244.
15. Merrick GS, Butler WM, Dorsey AT et al. Influence of prophylactic dexamethasone on edema following prostate brachytherapy. Tech Urol 2000; 6: 117-122.
16. Kuban DA, Levy LB, Potters L et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006; 65: 1487-1493.
17. Penney KL, Stampfer MJ. The time is ripe for a randomized trial of metformin in clinically localized prostate cancer. J Clin Oncol 2013; 31: 3054-3055.
18. Aus G, Abrahamsson PA, Ahlgren G et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: A 7-year follow-up of a randomized controlled trial. BJU Int 2002; 90: 561-566.
19. Soloway MS, Pareek K, Sharifi R et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002; 167: 112-116.
20. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 2002; 360: 103-106.
21. D'Amico AV, Manola J, Loffredo M et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004; 292: 821-827.
22. Roach M, 3rd, Bae K, Speight J et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 2008; 26: 585-591.